Trial Profile

Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid beta Antibody in Patients With Alzheimer's Disease.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solanezumab (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Registrational
Acronyms EXPEDITION-EXT
Sponsors Eli Lilly and Company

Most Recent Events

18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record. (17 Feb-2017)
29 Mar 2017 This trial has been completed in Spain (End date:2017-02-17) as per European Clinical Trials Database record.
07 Mar 2017 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com